Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

Kurosawa, Saiko; Yamaguchi, Takuhiro; Mori, Takehiko; Kanamori, Heiwa; Onishi, Yasushi; Emi, Nobuhiko; Fujisawa, Shin; Kohno, Akio; Nakaseko, Chiaki; Saito, Bungo; Kondo, Tadakazu; Hino, Masayuki; Nawa, Yuichiro; Kato, Shingo; Hashimoto, Akiko; Fukuda, Takahiro

doi:10.1038/bmt.2015.137

Cited by 48 publications

(40 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the allo- HSCT patients without GvHD, the physical QoL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QoL than the chemotherapy patients. 27 …”

Section: Acute Myeloid Leukaemia and Holistic Needs Assessmentmentioning

confidence: 99%

Treat patient, not just the disease: holistic needs assessment for haematological cancer patients

Islam

2018

Oncol Rev

View full text Add to dashboard Cite

Haematological malignancies can have devastating effects on the patients’ physical, emotional, psycho-sexual, educational and economic health. With the improvement of therapies patients with these malignancies are living longer, however significant proportion these patient show poor quality of life (QoL) due to various physical and psychological consequences of the disease and the treatments. Health-related QoL (HRQoL) is multi-dimensional and temporal, relating to a state of functional, physical, psychological and social/family well-being. Compared with the general population, HRQoL of these patients is worse in most dimensions. However without routine holistic need assessment (HNA), clinicians are unlikely to identify patients with clinically significant distress. Surviving cancer is a chronic life-altering condition with several factors negatively affecting their QoL, such as psychological problems, including depression and excessive fear of recurrence, as well as social aspects, such as unemployment and social isolation. These need to be adequately understood and addressed in the healthcare of long-term survivors of haematological cancer. Applying a holistic approach to patient care has many benefits and yet, only around 25% of cancer survivors in the UK receive a holistic needs assessment. The efforts of the last decade have established the importance of ensuring access to psychosocial services for haematological cancer survivors. We need to determine the most effective practices and how best to deliver them across diverse settings. Distress, like haematological cancer, is not a single entity, and one treatment does not fit all. Psychosocialoncology needs to increase its research in comparative effectiveness.

show abstract

Section: Acute Myeloid Leukaemia and Holistic Needs Assessmentmentioning

confidence: 99%

Treat patient, not just the disease: holistic needs assessment for haematological cancer patients

Islam

2018

Oncol Rev

View full text Add to dashboard Cite

show abstract

“…This is often counterbalanced by a higher incidence of graft-versushost disease (GVHD) and a higher non-relapse mortality (NRM) [5,6]. All these individual complications (i.e., GHVD, relapse or death) significantly impact HSCT outcomes with impairment of quality of life and long-term survival [7,8]. Classical endpoints such as leukemia-free survival (LFS) or GVHD only reflect some of the main HSCT outcomes, but each of these outcomes is clinically meaningful and closely linked to each other, so that each one should be taken into account when assessing transplant outcomes.…”

Section: Introductionmentioning

confidence: 99%

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia

Battipaglia

Ruggeri

Labopin

et al. 2018

Bone Marrow Transplant

View full text Add to dashboard Cite

Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.

show abstract

“…Advances in allogeneic hematopoietic cell transplantation (allo-HCT) and expanding indications for its use in recent years have resulted in a growing number of transplant survivors [1][2][3][4][5]. Quality of life (QoL) after allo-HCT and longterm survivorship care have been receiving more attention [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

Kurosawa¹,

Oshima

Yamaguchi

et al. 2017

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Knowing the impact of chronic graft-versus-host disease (GVHD) on quality of life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study to examine the relationship between patient-reported QoL as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and visual analogue scale (VAS) and chronic GVHD defined by the National Institutes of Health (NIH) criteria. Recipients of allo-HCT for hematologic disease between 1995 and 2009 aged ≥ 16 years at transplant and ≥20 years at the time of the survey who were relapse-free were eligible. A total of 1140 pairs of patient and physician questionnaires were included in the analysis. By NIH global severity score, QoL scores in all aspects were significantly lower in patients with higher global and organ-specific severity grades, independent of background variables. Compared with patients without GVHD symptoms, those with mild symptoms had impaired physical and general QoL according to global severity score and organ-specific scores except for the genital tract. Mild symptoms in the lungs, gastrointestinal tract, and joints and fascia were associated with clinically meaningful deterioration of physical QoL. VAS scores provided by physicians were generally higher than those provided by patients. Differences between scores reported by patients and physicians were larger for patients with no or mild GVHD symptoms. Our findings based on more than 1000 long-term survivors after HCT enabled us to identify a target of care, informing survivorship care protocols to improve post-transplantation QoL.

show abstract

Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

Cited by 48 publications

References 50 publications

Treat patient, not just the disease: holistic needs assessment for haematological cancer patients

Treat patient, not just the disease: holistic needs assessment for haematological cancer patients

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia

Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

Contact Info

Product

Resources

About